

HITIQ Quarterly Activities Report June 2025

Highlights

- > **PROTEQT Commercial Launch:** HITIQ successfully launched its flagship PROTEQT smart mouthguard system in the consumer market, marking a pivotal shift from elite sports to grassroots community athletics.
- > **Exclusive Global Shock Doctor Partnership:** Secured a landmark 5-year exclusive global agreement with Shock Doctor, the world's #1 mouthguard brand, creating the world's first self-fit instrumented concussion mouthguard with production scaling to 100,000 units by 2026.
- > **Strategic Grassroots Partnerships Expanded:** New multi-year partnerships secured with AFL Barwon (25,000+ players) and South Metro Junior Football League (10,000+ players), complementing existing agreements with VAFA and Westfield Sports High.
- > **Capital Raising Completed:** Successfully raised \$1.9 million through a placement (\$680k) and partially underwritten rights issue \$1.2 million to fund consumer market expansion and global manufacturing capacity.
- > **Enhanced R&D Funding:** Additional \$420,000 drawdown from R&D loan facility, bringing total utilisation to \$1.42 million with RDTI refund expected by December 2025.
- > **Additional Loan** from Harmil Angel Investments of \$500,000 payable in 6 months.

Operational and Strategic Updates

HITIQ Limited (ASX: HIQ) achieved transformative commercial milestones during the June 2025 quarter, successfully launching its consumer-focused PROTEQT system and establishing infrastructure for global scale.

PROTEQT: World-First Technology Partnership

Following a two-year co-development phase, HITIQ signed an exclusive global manufacturing and distribution agreement with Shock Doctor. This groundbreaking partnership delivers the first self-fit instrumented mouthguard, integrating HITIQ's proprietary sensor technology into Shock Doctor's proven chassis design.

The co-branded HITIQ/SHOCK PROTEQT mouthguard combines impact detection, symptom assessment, and 7-day telehealth support using the Sports Concussion Assessment Tool (SCAT).

Production is underway through Stang Precision for 2025 requirements, with manufacturing capacity scaling to 100,000 units in 2026. HITIQ will distribute directly in Australia (AUD \$349 including GST) and the UK (GBP £199 including VAT).

Grassroots Market Expansion

HITIQ secured new multi-year partnerships with AFL Barwon (25,000+ players) and South Metro Junior Football League (10,000+ players), establishing HITIQ as Official Concussion Technology Partner for both organisations. Combined with existing VAFA (15,000+ players) and Westfield Sports High partnerships, HITIQ now has direct access to over 50,000 athletes across Australia's community sports sector.

The addressable market represents significant revenue potential: Australia's collision sports participants total approximately 971,050 athletes (TAM of ~\$310 million), with international markets in the UK and US adding a further \$3.75 billion opportunity.

Market Outlook

HITIQ's successful PROTEQT launch positions the Company to capture market share in the growing concussion management sector. The combination of proven elite sports technology, strategic community partnerships, and global manufacturing capability creates a scalable platform for sustainable growth.

With industry estimates suggesting significant portions of Australia's 100,000 annual sports-related concussions go undetected at grassroots level, PROTEQT addresses a critical market need through accessible, easy-to-use technology.

Upcoming Initiatives

- Shareholder Town Hall webinar on PROTEQT system details.
- Expansion of community sports partnerships across rugby league and union.
- International market development in the UK and US.
- Product enhancement for additional recurring revenue streams.

Financial

The company had cash reserves of A\$934,689 as at 30th June 2025.

Capital Raising

HITIQ raised \$1.9 million comprising:

- **Placement:** \$680,000 through 30,909,091 shares at \$0.022 per share
- **Rights Issue:** Up to \$2.9million to eligible shareholders, partially underwritten to \$1.2 million.
- **Option Attachments:** One free attaching option (exercisable at \$0.022, expiring December 30, 2028) for every two shares issued.

The company is looking to close out the shortfall from the rights issue in the coming weeks.

Use of Funds

- Manufacturing capacity expansion (22.5%)
- USA market expansion (25%)
- Product enhancement (15%)
- Business development and marketing (15%)
- Continued R&D and AI capability (12.5%)
- Working capital and costs (10%)

R&D Funding and Loan

An additional \$420,000 drawdown from R&D loan facility with Rockford RDF Pty Ltd brings total utilisation to \$1.22 million, with repayment expected on or before December 31, 2025.

A short-term Loan of \$500,000 from Harmil Angel Investments repayable on or before December 31, 2025.

Related Party Payments

As advised in Section 6.1 in the Appendix 5c for the period, payments to, or an associate of, a related party of the entity during the quarter totaled \$120,829 comprising executive and non-executive director remuneration, company secretarial services, and professional advisory fees.

• Executive Director Salary and Superannuation	\$72,046
• Non-Executive Director Fees	\$37,668
• Company Secretarial Fees provided by Fernville Group,	
o A related party of Non-Executive Director, Mr. James Barrie	\$8,621
• Bookkeeping, Accounting and Taxation Services provided by Optima Partners,	
o A related party of Non-Executive Director, Mr. Philip Carulli	\$21,783

As per the resolution passed at the 2024 AGM directors also received payments in lieu of outstanding Directors Fees.

Conclusion

The June 2025 quarter represents a watershed moment for HITIQ, successfully transitioning from development to commercial operations while establishing the foundation for global scale. The Company's strategic partnerships, innovative technology, and strong financial position provide a robust platform for capturing significant growth opportunities in the consumer concussion management market.

- ENDS -

Authorised for release by the Board of Directors.

For more information, contact: investors@hitiq.co

HIT·IQ

About Us

At HITIQ we build world class concussion management technology that protects what matters most.

We're your one stop shop for head impact monitoring, assessment and management.

Our products and technology enable you to play with confidence.

From elite to grassroots, we're committed to providing peace of mind and encouraging even greater participation in sport.



APPENDIX 4C

Quarterly cash flow report for entities
subject to listing rule 4.7b

Name of entity

HITIQ Limited

ABN

53 609 543 213

Quarter ended ("current quarter")

30th June 2025

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (12 months) \$A'000
1.	Cash flows from operating activities		
1.1	Receipts from customers	178	731
1.2	Payments for		
	(a) research and development	(512)	(1,087)
	(b) product manufacturing and operating costs		
	(c) advertising and marketing	(73)	(295)
	(d) leased assets		
	(e) staff costs	(1,041)	(3,886)
	(f) administration and corporate costs	(171)	(2,194)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	-	4
1.5	Interest and other costs of finance paid	-	-
1.6	Income taxes paid	-	-
1.7	Government grants and tax incentives	-	1,600
1.8	Other (Foreign Exchange Loss)	-	118
1.9	Net cash from / (used in) operating activities	(1,619)	(5,009)

2.	Cash flows from investing activities		
2.1	Payments to acquire or for:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	(4)	(27)
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (12 months) \$A'000
2.2	Proceeds from disposal of:		
	(g) entities	-	-
	(h) businesses	-	-
	(i) property, plant and equipment	-	-
	(j) investments	-	-
	(k) intellectual property	-	-
	(l) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	Net cash from / (used in) investing activities	(4)	(27)

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	1,489	1,943
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	(81)	(81)
3.5	Proceeds from borrowings	920	5,220
3.6	Repayment of borrowings	-	(1,687)
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	Net cash from / (used in) financing activities	2,328	5,395

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	230	576
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(1,619)	(5,009)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(4)	(27)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	2,328	5,395

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (12 months) \$A'000
4.5	Effect of movement in exchange rates on cash held	-	-
4.6	Cash and cash equivalents at end of period	935	935

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	935	230
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	935	230

6.	Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	140
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-
Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.		

7.	Financing facilities Note: the term "facility" includes all forms of financing arrangements available to the entity. Add notes as necessary for an understanding of the sources of finance available to the entity.	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
7.1	Loan facilities	5,400	5,400
7.2	Credit standby arrangements	-	-
7.3	Other (please specify)	-	-
7.4	Total financing facilities	5,400	5,400
7.5	Unused financing facilities available at quarter end		-
7.6	Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		

R&D Finance facility of \$1,220,000 with Rockford Pty Ltd. Secured against R&D Refund. Term 150 days, the R&D refund, interest rate 15% per annum. Additionally, the company has entered into a convertible note facility with its major shareholder, Harmil Angel Investments for \$4,600,000 for a period of 12 months at an interest rate of 12.5%, and the final \$500,000 was drawn on the 22 January 2025.

8.	Estimated cash available for future operating activities	\$A'000
8.1	Net cash from / (used in) operating activities (item 1.9)	(1,653)
8.2	Cash and cash equivalents at quarter end (item 4.6)	935
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	935
8.5	Estimated quarters of funding available (item 8.4 divided by item 8.1)	0.57
	<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>	
8.6	If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1	Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
	Answer: Yes, cashflows to continue	
8.6.2	Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
	Answer: The company is continuing to raise capital under its shortfall offer in accordance with the rights issue Prospectus dated 12 June 2025.	
8.6.3	Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?	
	Answer: Yes, the company expects to be able to continue its operations and meet its business objectives on the basis of the expected implementation and completion of the activities outlined in 8.6.2.	
	<i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i>	

Compliance statement

- This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- This statement gives a true and fair view of the matters disclosed.

Date: 30 July 2025

Authorised by: The Board of HITIQ Limited
(Name of body or officer authorising release – see note 4)

1.1 Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – e.g., Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.